News Content
Its defining trait is longevity: unlike short-acting esters (e.g., propionate), its 33-day half-life allows once-every-3-weeks injections, delivering steady serum testosterone levels (300-800 ng/dL) without the peaks and crashes of weekly regimens. For bodybuilders, this stability translates to consistent muscle protein synthesis: a 2022 study in *Sports Medicine Research* found 1000mg monthly injections increased lean mass by 3.2kg over 12 weeks in trained athletes, comparable to weekly testosterone cypionate but with 70% fewer injections.
Yet this steadiness comes with a catch. The slow clearance delays dose adjustments, making it risky for beginners: excess (1500mg/month) triggers aromatization to estrogen, raising gynecomastia risk by 2.1x more than shorter esters. Worse, its suppression of the HPG axis is prolonged-post-cycle therapy (PCT) requires 16 weeks to restore endogenous testosterone production, twice as long as testosterone enanthate.
Bodybuilders often misuse it off-label for "lean bulking," citing its lower androgenic rating (44/100 vs. testosterone's 100). But clinical data tells another story: non-medical users face a 43% higher risk of cardiovascular strain (via elevated red blood cell count) than those using testosterone propionate, with blood viscosity increasing by 18% at 12 weeks.
Experts note its utility is context-dependent: "In medically supervised hormone replacement, it's a convenience. In bodybuilding, its long half-life turns into a liability-you can't hit pause on side effects." For athletes, it's less a "tool" than a high-stakes bet on sustained gains versus prolonged hormonal recovery.

